GPs continue to play a vital role in systematically identifying patients with non-valvular atrial fibrillation (NVAF), and initiating oral anticoagulation therapy where appropriate.

To help you with managing NVAF in the community, mdBriefcase (supported by Boehringer Ingelheim) presents an expert panel of healthcare professionals who share their thoughts on managing and treating four different patient types. Join Dr. Brad McKay, Prof. Andrew Sindone, Dr. Timothy Ang and Prof. Christopher Ward – as they discuss each patient case in depth.

Faculty

Dr Brad McKay
MBBS, FRACGP
General Practitioner
Professor Andrew Sindone
B.Med(Hons), MD, FRACP, FCSANZ, FNHFA
Cardiologist
Dr Timothy Ang
MBBS, FRACP, CCINR
Consultant Neurologist
Professor Christopher Ward
BMedSc, MBChB w Dist. PhD (Monash), FRACP, FRCPA Clinical Haematologist

Duration

1 hr

# of Credits 2.0

Total Points: 2 Point(s) (Category 2)

Accreditation

This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program.

Learning Outcomes

On completion of this program, participants will be better able to:

  • Systematically identify patients with non-valvular atrial fibrillation (NVAF), through appropriate screening and ECG interpretation, and immediately initiate oral anticoagulation therapy where appropriate
  • Communicate the benefits versus risks of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin to patients with NVAF based on evidence from randomised controlled trials (RCTs) and real-world evidence
  • Address some of the clinical challenges encountered when managing patients with NVAF, including screening for and managing comorbidities, and minimising the risk of bleeding
  • Review and apply management strategies for NVAF patients who require emergency surgery or experience a life-threatening bleed
Start course
 
 
Notification Title